Imipenem/Cilastatin Sodium/Funobactam

亚胺培南/西司他丁钠/福诺巴坦

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameImipenem/Cilastatin Sodium/Funobactam
Drug Alias Name亚胺培南西司他丁钠福诺巴坦亚胺西福
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta Lactamase inhibitorsBacterial penicillin-binding protein inhibitorsEnzymes inhibitors
TargetsBeta LactamaseBacterial penicillin-binding proteinEnzymes
Therapy Area/IndicationsHospital-acquired pneumoniaPneumonia, Ventilator-AssociatedGram-Negative Bacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes ImipenemCilastatin SodiumFunobactam
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesEvopoint Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEvopoint Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsHospital-acquired pneumoniaPneumonia, Ventilator-AssociatedGram-Negative Bacterial Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A